Minimal tumor necrosis factor receptor binding protein: Optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein

European Cytokine Network

Volumn 9, Issue 3, 1998, Pages 255-262

  Corcoran, Anne E ^a,b   Scallon, Bernard J ^c   Trinh, Han ^c   Chernajovsky, Yuti ^a   Ghrayeb, John ^c   Feldmann, Marc ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c CENTOCOR INC   (United States)

Author keywords

IgG chimeras; p55 TNF receptor; TNF binding

Indexed keywords

BINDING PROTEIN; CYSTEINE; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; TUMOR NECROSIS FACTOR RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CHIMERA; CYTOTOXICITY; DRUG ACTIVITY; HUMAN; RECEPTOR BINDING; SEPTIC SHOCK;

ANIMALS; ANTIGENS, CD; CELL SURVIVAL; DIMERIZATION; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN CONSTANT REGIONS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; LIPOPOLYSACCHARIDES; LYMPHOTOXIN-ALPHA; MICE; MODELS, MOLECULAR; POLYMERASE CHAIN REACTION; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031770145     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Beutler B, Cerami A. 1988. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57: 505.
2. Larrick J W, Wright S C. 1990. Cytotoxic mechanism of tumor necrosis factor-alpha. (Review) FASEB J 4: 3215.
3. Brennan F M, Chantry D, Jackson A, Maini R, Feldmann M. 1989. Inhibitory effects of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet ii: 244.
4. Feldmann M, Brennan F M, Chantry D, Haworth C, Turner M, Abney E, Buchan G, Barrett K, Barkley D, Chu A, Field M, Maini R N. 1990. Cytokine production in the rheumatoid joint: implications for treatment. Ann. Rheum. Dis. 49: 480.
5. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G. 1991. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 10: 4025.
6. Stauber G B, Aggarwal B B. 1989. Characterization and affinity cross-linking of of receptors for human recombinant lymphotoxin (Tumour necrosis factor-β) on a human histiocytic lymphoma cell line, U-937. J. Biol. Chem. 264: 3573.
7. Seckinger P, Isaaz S, Dayer J M. 1989. Purification and biologic characterization of a specific tumor necrosis factor-alpha inhibitor. J. Biol. Chem. 264: 11966.
8. Engelmann H, Novick D, Wallach D. 1990. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J. Biol. Chem. 265: 1531.
9. Porteu F, Brockhaus M, Wallach D, Engelmann H, Nathan C F. 1991. Human neutrophil elastase releases a ligand-binding fragment from the 75 kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. J. Biol. Chem. 266: 18846.
10. Cope A, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones A C, Brennan F M, Maini R N, Wallach D, Feldmann M. 1992. Increased levels of soluble tumour necrosis factor receptors in the sera and synovial fluids of patients with rheumatic diseases. Arthritis Rheum. 35: 1160.
11. Aderka D, Englemann H, Hornik V, Skornick Y, Levo Y, Wallach D, Kushtai G. 1991. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 51: 5602.
12. Williams R O, Feldmann M, Maini R N. 1992. Anti-tumour necrosis factor-ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89: 9784.
13. Elliott M J, Maini R N, Feldmann M, Kalden J R, Antoni C, Smolen J S, Leeb B, Breedveld F C, Macfarlane J D, Bijl H, Woody J N. 1994. Randomized double blind comparison of a chimeric monoclonal antibody to tumour necrosis factor-α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105.
14. Rankin E C, Choy E H S, Kassimos D, Kingsley G H, Sopwith A M, Isenberg D A, Panayi G S. 1995. The therapeutic effects of an engineered human anti-tumour necrosis factor-alpha antibody (CDP571) in rheumatoid arthritis. Br. J. Rheumatol. 34: 334.
15. Lorenz H M, Antoni C, Valerius T, Repp R, Grunke M, Schwerdtner N, Nusslein H, Woody J, Kalden J R, Manger B. 1996. In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis. Short term cellular and molecular effects. J. Immunol. 156: 1646.
16. Targan S R, Hanauer S B, van Deventer S J, Mayer L, Present D H, Braakman T, DeWoody K L, Schaible T F, Rutgeerts P J. 1997 A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor-alpha for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med. 337: 1029
17. Stack W A, Mann S D, Roy A J, Heath P, Sopwith M, Freeman J, Holmes G, Long R, Forbes A, Kamm M A. 1997. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. Lancet 349: 521.
18. Elliott M J, Maini R N, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody J N. 1994. Repeated therapy with monoclonal antibody to tumour necrosis factor-α (cA2) in patients with rheumatoid arthritis. Lancet 344: 1125.
19. Ashkenazi A, Marsters S A, Capon D J, Chamow S M, Figari I S, Pennica D, Goeddel D V, Palladino M A, Smith D H. 1991. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc. Natl. Acad. Sci. USA 88: 10535.
20. Peppel K, Crawford D, Beutler B. 1991. A tumour necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J. Exp. Med. 174: 1483.
21. Lesslauer W, Tabuchi H, Gentz R, Brockhaus M, Schlaeger E J, Grau G, Piguet P F, Pointaire P, Vassalli P, Loetscher H. 1991. Recombinant soluble tumour necrosis factor receptor proteins protect mice from lipopolysaccharide-induced lethality. Eur. J. Immunol. 21: 2883.
22. Scallon B J, Trinh H, Nedelman M, Brennan F M, Feldmann M, Ghrayeb J. 1995. Functional comparisons of different Tumor Necrosis Factor Receptor/IgG fusion proteins. Cytokine 7: 759.
23. Bertini R, Delgado R, Faggioni R, Gascon M P, Ythier A, Ghezzi P. 1993. Urinary TNF-binding protein (TNF soluble receptor) protects mice against the lethal effect of TNF and endotoxic shock. Eur. Cytokine Netw: 4: 39.
24. Moreland L W, Baumgartner S W, Schiff M H, Tindall E A, Fleischmann R M, Weaver A L, Ettlinger R E, Cohen S, Koopman W J, Mohler K, Widmer M B, Blosch C M. 1997. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Gc fusion protein. N. Engl. J. Med. 337: 141.
25. Gray P W, Barrett K, Chantry D, Turner M, Feldmann M. 1990. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF binding protein. Proc. Natl. Acad. Sci. USA 87: 7380.
26. Smith C A, Davis T, Anderson D, Solam L, Beckmann M P, Jerzy R, Dower S K, Cosman D, Goodwin R G. 1990. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248: 1019.
27. Banner D W, D'Arcy A, Janes W, Gentz, R, Schoenfeld H J, Broger C, Loetscher H, Lesslauer W. 1993. Crystal structure of the soluble human 55 kd TNF receptor-human TNF-β complex: implications for TNF receptor activation. Cell 73: 431.
28. Corcoran A E, Barrett K, Turner M, Brown A, Kissonerghis A M, Gadnell M, Gray P W, Chernajovsky Y, Feldmann M. 1994. Characterization of ligand binding by the human p55 tumour-necrosis-factor receptor. Involvement of individual cysteine-rich repeats. Eur. J. Biochem. 223: 831.
29. Looney J E, Knight D M, Arevalo-Moore M, Trinh H, Pak K Y, Dalesandro M R, Rieber E P, Riethmuller G, Daddona P E, Ghrayeb J. 1992. High-level expression and characterization of a mouse-human chimeric CD4 antibody with therapeutic potential. Hum. Antibodies Hybridomas 3: 191.
30. Knight D M, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B J, Moore M A, Vilcek J, Daddona P E, Ghrayeb J. 1993. Construction and initial characterization of a mouse/human chimeric anti-TNF antibody. Mol. Immunol. 30: 1443.
31. Espevik T, Nissen-Meyer J. 1986. A highly sensitive cell line. WEHI 164, clone 13, for measuring cytotoxic factor/tumour necrosis factor from human monocytes. J. Immunol. Methods 95: 99.
32. Brockhaus M, Schoenfeld H J, Schlaeger E J, Hunziker W, Lesslauer W, Loetscher H. 1990. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl. Acad. Sci. USA 87: 3127.
33. Lehmann V, Freundenberg M M, Galanos C. 1987. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine treated mice. J. Exp. Med. 165: 657.
34. Jones E Y, Stuart D I, Walker N P. 1989. Structure of tumour necrosis factor. Nature 338: 225.
35. Eck M J, Ultsch M, Rinderknecht E, de Vos A M, Sprang S R. 1992. The structure of human lymphotoxin (tumor necrosis factor-β) at 1.9-A resolution. J. Biol. Chem. 267: 2119.
36. De Togni P, Goellner J, Ruddle N H, Streeter P R, Fick A, Mariathasan S, Smith S C, Carlson R, Shornick L P, Strauss-Schoenberger J, Russell J H, Karr R, Chaplin D D. 1994. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 264: 703.
37. Koni P A, Sacca R, Lawton P, Browning J L, Ruddle N H, Flavell R A. 1997. Distinct roles in lymphoid organogenesis for lymphotoxins α and β revealed in lymphotoxin β-deficient mice. Immunity 6: 491.
38. Marsters S A, Frutkin A D, Simpson N J, Fendly B M, Ashkenazi A. 1992. Identification of cysteine-rich domains of the type I tumor necrosis factor receptor involved in ligand binding. J. Biol. Chem. 267: 5747.